- Investigator
- Mohammad Ilyas
- Ages
- 0 Years - 12 Years
- Sexes
- All
Clinical trials
-
Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 12 Years of Age with Hyperkalaemia -
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) - Investigator
- Gurjit S Kaeley
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (JOURNEY) - Investigator
- Michael D Schweitzer Barrios
- Ages
- 40 Years - 80 Years
- Sexes
- All
-
蹤獲扦 JAX Hernia Outcomes Data Bank - Investigator
- Jana M Sacco
- Ages
- 18 Years - N/A
- Sexes
- All
-
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC who are BCG Na簿ve/Received Incomplete BCG Treatment - Investigator
- Kethandapatti Balaji
- Ages
- 18 Years - 100 Years
- Sexes
- All
-
Selatogrel Outcome Study in suspected Acute Myocardial Infarction (SOS-AMI) - Investigator
- Francesco Franchi
- Ages
- 18 Years - N/A
- Sexes
- All
-
Study of BD ORC Original Absorbable Hemostat Compared with Surgicel簧 Original Absorbable Hemostat - Investigator
- Kethandapatti Balaji
- Ages
- 22 Years - 101 Years
- Sexes
- All
-
ReMEDy2: A Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke - Investigators
- Benjamin T Alwood, Scott L Silliman
- Ages
- 18 Years - 90 Years
- Sexes
- All
-
ReMEDy2: A Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke - Investigators
- Benjamin T Alwood, Scott L Silliman
- Ages
- 18 Years - 90 Years
- Sexes
- All